Education
About Us
Working with TipRanks
Follow Us
ARS Pharmaceuticals (SPRY)
NASDAQ:SPRY
SPRY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.55 - $18.51
Previous CloseN/A
Volume456.05K
Average Volume (3M)2.11M
Market Cap
$1.38B
Enterprise Value$719.44M
Total Cash (Recent Filing)$374.20M
Total Debt (Recent Filing)$3.48M
Price to Earnings (P/E)183.2
Beta1.95
Next Earnings
May 19, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding98,119,804
10 Day Avg. Volume2,229,221
30 Day Avg. Volume2,105,413
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)467.76
Price to Cash Flow (P/CF)-20.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.73K
Enterprise Value/Ebitda-11.90
Forecast
1Y Price Target
$33.00Price Target Upside134.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
ARS Pharmaceuticals News
PremiumCompany Announcements
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
PremiumCompany Announcements
ARS Pharmaceuticals Reports Strong 2024 Financial Results
---
Bulls Say, Bears Say
Bulls Say
Direct-to-Consumer MarketingPlans to roll out a broader direct-to-consumer campaign to raise awareness among physicians, patients, and caregivers should help position neffy well ahead of the typical 'back-to-school' surge in epinephrine prescribing.
Insurance And Payer CoverageManagement announced that UnitedHealthcare will add neffy to its formulary with unrestricted coverage, boosting market access.
Product Approval And Market ExpansionRecent approval of neffy 1 mg for the 15-30 kg Type 1 allergy pediatric population is expected to enhance its market presence.
Bears Say
Operating ExpensesNew FY25 operating expense guidance implies a step-up versus FY24 levels, signaling increased costs for the company.
Prior Authorization ChallengesCurrent prior authorization requirements have been a logistical hurdle for some prescribers of neffy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SPRY FAQ
What was ARS Pharmaceuticals’s price range in the past 12 months?
ARS Pharmaceuticals lowest stock price was $7.55 and its highest was $18.51 in the past 12 months.
What is ARS Pharmaceuticals’s market cap?
ARS Pharmaceuticals’s market cap is $1.38B.
When is ARS Pharmaceuticals’s upcoming earnings report date?
ARS Pharmaceuticals’s upcoming earnings report date is May 19, 2025 which is in 34 days.
How were ARS Pharmaceuticals’s earnings last quarter?
ARS Pharmaceuticals released its earnings results on Mar 20, 2025. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of -$0.238 by $0.718.
Is ARS Pharmaceuticals overvalued?
According to Wall Street analysts ARS Pharmaceuticals’s price is currently Undervalued.
Does ARS Pharmaceuticals pay dividends?
ARS Pharmaceuticals does not currently pay dividends.
What is ARS Pharmaceuticals’s EPS estimate?
ARS Pharmaceuticals’s EPS estimate is -0.34.
How many shares outstanding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 98,119,804 shares outstanding.
What happened to ARS Pharmaceuticals’s price movement after its last earnings report?
ARS Pharmaceuticals reported an EPS of $0.48 in its last earnings report, beating expectations of -$0.238. Following the earnings report the stock price went up 22.833%.
Which hedge fund is a major shareholder of ARS Pharmaceuticals?
Currently, no hedge funds are holding shares in SPRY
---
ARS Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (134.88% Upside)
$33.00 (134.88% Upside)
Blogger Sentiment
Bullish
SPRY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 695.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.05%
12-Months-Change
Fundamentals
Return on Equity
3.28%
Trailing 12-Months
Asset Growth
50.59%
Trailing 12-Months
Company Description
ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with severe allergies. The company's flagship product, Neffy, is a needle-free epinephrine nasal spray designed as a rapid treatment for severe allergic reactions, including anaphylaxis. ARS Pharmaceuticals aims to provide effective and user-friendly solutions to improve patient outcomes and enhance the quality of life for individuals with life-threatening allergic conditions.
---
SPRY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive trajectory for ARS Pharmaceuticals, highlighted by the successful launch and growing adoption of neffy, substantial payer coverage progress, and strong financial positioning. However, challenges with prior authorizations and delays in some payer formulary additions present obstacles that need addressing. Overall, the company is well-placed for significant growth, with strategies to overcome existing challenges.Read More>---
SPRY Stock 12 Month Forecast
Average Price Target
$33.00
▲(134.88% Upside)
Technical Analysis
Mesoblast
―
Immunocore Holdings
―
Edgewise Therapeutics
―
Vera Therapeutics
―
CG Oncology, Inc.
―
Best Analysts Covering SPRY
1 Year
1 Year Success Rate
8/10 ratings generated profit
1 Year Average Return
+101.04%
initiated a buy rating 2 months ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +101.04% per trade.
---